19-23649-shl Doc 664 Filed 12/18/19 Entered 12/18/19 14:22:54 Main Document Pg 1 of 7
19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 13 of 20

UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK	1 :		
In re:	Chapter 11		
PURDUE PHARMA L.P., et al.,	Case No. 19-23649 (RDD)		
Debtors. ¹	(Jointly Administered)		
AFFIDAVIT AND DISCLOSURE	STATEMENT OF Margaret J. Strange,		
ON BEHALF OF _ Purdue	Pharma L.P.		
STATE OF Connecticut) s.s.: COUNTY OF Hartford)			
Margaret J. Strange_, being duly sworn,	upon his oath, deposes and says as follows:		
1. I am a Principal	of _Jackson Lewis P.C,		
located at 90 State House Square, 8th Floor, Hartford,	CT 06103 (the " Firm ").		
2. Purdue Pharma L.P. and	its affiliates that are debtors and debtors in		
possession in the above-captioned chapter 11 cas	es (collectively, the "Debtors"), have requested		
that the Firm provide services to the Debtors,	and the Firm has consented to provide such		
services (the "Services").			

litigation, labor and employment advice and counsel including assistance with affirmative action plans and advice.

The Services include, but are not limited to, the following: Employment

3.

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

19-23649-shl Doc 664 Filed 12/18/19 Entered 12/18/19 14:22:54 Main Document Pg 2 of 7 19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 14 of 20

- 4. The Firm may have performed services in the past and may perform services in the future, in matters unrelated to these chapter 11 cases, for persons that are parties in interest in the Debtors' chapter 11 cases. As part of its customary practice, the Firm is retained in cases, proceedings, and transactions involving many different parties, some of whom may represent or be claimants or employees of the Debtors, or other parties in interest in these chapter 11 cases. The Firm does not perform services for any such person in connection with these chapter 11 cases. In addition, the Firm does not have any relationship with any such person, such person's attorneys, or such person's accountants that would be adverse to the Debtors or their estates with respect to the matters on which the Firm is to be retained.
- 5. Neither I, nor any principal of, or professional employed by the Firm has agreed to share or will share any portion of the compensation to be received from the Debtors with any other person other than principals and regular employees of the Firm.
- 6. Neither I nor any principal of, or professional employed by the Firm, insofar as I have been able to ascertain, holds or represents any interest materially adverse to the Debtors or their estates with respect to the matters on which the Firm is to be retained.

19-23649-shl Doc 664 Filed 12/18/19 Entered 12/18/19 14:22:54 Main Document Pg 3 of 7
19-23649-rdd Doc 548 Filed 11/26/19 Entered 11/26/19 16:31:39 Main Document Pg 15 of 20

- 7. As of the commencement of this chapter 11 case, the Debtors owed the Firm \$422.50 in respect of prepetition services rendered to the Debtors.
- 8. The Firm is conducting further inquiries regarding its retention by any creditors of the Debtors, and upon conclusion of this inquiry, or at any time during the period of its employment, if the Firm should discover any facts bearing on the matters described herein, the Firm will supplement the information contained in this Affidavit.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct, and that this Affidavit and Disclosure Statement was executed on Vecantar 12, 2019, at Hart ford.

Affiant Name Margaret J. Strange

SWORN TO AND SUBSCRIBED before Me this /a day of December, 2019

Notary Public

Cammisian expires: 11/30/24

SOUTHERN DISTRICT OF NEW YORK	
In re:	Chapter 11

PURDUE PHARMA L.P., et al.,

Debtors.4

UNITED STATES BANKRUPTCY COURT

Case No. 19-23649 (RDD)

(Jointly Administered)

RETENTION QUESTIONNAIRE

TO BE COMPLETED BY PROFESSIONALS EMPLOYED by Purdue Pharma L.P. and its affiliates that are debtors and debtors in possession in the above-captioned cases (collectively, the "**Debtors**").

All questions **must** be answered. Please use "none," "not applicable," or "N/A," as appropriate. If more space is needed, please complete on a separate page and attach.

1. Name and address of professional:

Margaret J. Strange

Jackson Lewis P.C. 90 State House Square, 8th Floor Hartford, CT 06103

- 2. Date of retention: November 3, 1992
- 3. Type of services to be provided:

⁴ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

$15923649 \text{ rabi doe} \ 5464 \ \text{Filed} \ 12/26/19 \ \text{Entered} \ 12/26/19 \ 16:32:39 \ \text{Main Document} \ \text{Pg} \ 5806720$

		ment counsel			
Empl	oyment litigation	rvices to be provon, labor and er mative action p	mployment ad		ounsel includir
Arrang	gements for com	pensation (hourl	y, contingent,	etc.):	
	9				
H	ourly				
	ourly	hourly	rate	(if	applicable
(a)	Ourly Average	hourly	rate	(if	applicable
(a)	ourly	hourly	rate	(if	applicable
(a) \$ (b)	Ourly Average 343 Estimated av	hourly rerage monthly cooyed prepetition	ompensation b	·	
(a) \$ (b)	Ourly Average 343 Estimated av	rerage monthly c	ompensation b	·	
(a) \$ (b) (if con	Average 343 Estimated average averag	rerage monthly c	ompensation b	pased on prej	
(a) \$ (b) (if con	Average 343 Estimated average averag	rerage monthly cooyed prepetition	ompensation b	pased on prepared	petition retentio
(a) (b) (if cor	Average 343 Estimated average averag	rerage monthly colored prepetition	ompensation b	pased on prepared	petition retentio

radi doc 5464 filed 12/26/19 final 12/26/19 14:32:59 Main document pg 995720

	associate, or employee of the company:
I	Name:n/a
	Status:
1	Amount of claim: \$
]	Date claim arose:
l	Nature of claim:
_	
-	
	<u> </u>
]	<u>.</u>
]	

149236649 ratio does 5464 filled 121/261/19 finite and 121/261/19 14:32:354 Mean does when the part of 2057 20

Jackson Lewis P.C. represents a few Shareholder Parties in matters unrelated to the bankruptcy. None of these representations has accounted for more than 1% of the firm's annual revenue for the last five years.

10. Name and title of individual completing this form:

Margaret J. Strange, Attorney at Law

Dated: December 18, 2019